Unlike common nutraceuticals stocked in every health store, CJC-1295 is distributed via a global research peptide market that Rouet residents navigate through international suppliers. The key implication for Rouet researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Rouet researchers the practical tools to verify sourcing options methodically and source research-grade CJC-1295 with confidence.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Rouet researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The most consistent path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Warning signs in CJC-1295 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that do not include endotoxin results. The lyophilised (freeze-dried) form of CJC-1295 is always preferable to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Rouet
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. The primary quality-related safety risk in CJC-1295 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
